ATAI, DemeRx pursue ‘neurochemical reset’ for addiction in $22M JV

January 24, 2020 Articles 7:21 pm

People seeking treatment to overcome opioid addiction are often stymied by the treatment itself. Many don’t have access to drugs like methadone or buprenorphine or can’t make it to a clinic every day for a long enough time for the treatment to succeed. ATAI Life Sciences and DemeRx are setting up a joint venture to develop a one-and-done treatment for opioid dependence that works by giving people a “neurochemical reset.”

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on ATAI and innovations in the space.

Email
submit